- Optiscan Imaging (OIL) partners with software developer Prolucid Technologies to develop AI algorithms using confocal laser endomicroscopy (CLE) tech
- The companies will work to develop a processing pipeline to display the results of an AI algorithm to clinicians based on images from Optiscan’s platform technology
- The project will have an initial goal of developing an application to support image collection, processing, and tissue analytics to detect the presence of precancerous and cancerous cells
- The project is anticipated to span 18 to 24 months and will potentially enable clinicians to make faster decisions during clinical workflows
- Optiscan shares were last trading at 12.5 cents at 12:44 pm AEDT
Optiscan Imaging (OIL) has partnered with software developer Prolucid Technologies to develop artificial intelligence (AI) algorithms and telepathology workflows.
The two companies will use Optiscan’s confocal laser endomicroscopy (CLE) technology to develop a processing pipeline to display the results of an AI algorithm to clinicians based on images from Optiscan’s platform technology.
Together, Optiscan and Prolucid will focus on oral imaging and cancer detection, with the goal of developing a software-as-a-medical-device (SaMD) application to support image collection, processing, and tissue analytics to detect the presence of precancerous and cancerous cells.
The project is anticipated to span 18 to 24 months and will potentially enable clinicians to make faster decisions during clinical workflows.
The application will be used by trained healthcare professionals in a variety of hospital and clinical settings.
“The development of AI algorithms using our technology supports our vision to be at the forefront of enabling immediate, informed clinical decisions for healthcare professionals globally using digital microscopy,” Optiscan CEO and Managing Director Camile Farah said.
“We are delighted to be partnering with Prolucid Technologies on this cutting-edge innovation project, which will help clinicians achieve the best possible patient outcomes through the earlier detection, diagnosis and treatment of cancer.”
Meanwhile, Prolucid CEO Darcy Bachert said the collaboration between the two companies could “transform how professionals detect cancer”.
Optiscan shares were last trading at 12.5 cents at 12:44 pm AEDT.